Novo Nordisk A/S (NYSE:NVO) Stock Sale Reported by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $0.40 during mid-day trading on Tuesday, hitting $38.31. 9,333,253 shares of the company’s stock traded hands, compared to its average volume of 17,108,324. The firm has a 50 day simple moving average of $45.51 and a two-hundred day simple moving average of $43.87. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The stock has a market cap of $171.07 billion, a price-to-earnings ratio of 9.37, a P/E/G ratio of 1.27 and a beta of 0.74. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. On average, research analysts expect that Novo Nordisk A/S will post 3.54 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a $0.5786 dividend. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 20.05%.

Institutional Trading of Novo Nordisk A/S

Large investors have recently modified their holdings of the stock. QRG Capital Management Inc. raised its stake in Novo Nordisk A/S by 23.0% in the second quarter. QRG Capital Management Inc. now owns 175,187 shares of the company’s stock valued at $8,398,000 after purchasing an additional 32,756 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in Novo Nordisk A/S by 9.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 16,205 shares of the company’s stock worth $777,000 after buying an additional 1,444 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after buying an additional 71,684 shares during the period. State Street Corp increased its holdings in Novo Nordisk A/S by 0.6% in the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares during the period. Finally, Wellington Altus USA Inc. acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at approximately $115,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of a number of research reports. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, September 10th. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $64.94.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Ozempic cardiovascular data strengthens Novo’s competitive position. A retrospective real-world analysis presented at EASD found that adults with type 2 diabetes who increased Ozempic (semaglutide) to 2 mg had a statistically significant 6% lower risk of major cardiovascular events than patients who switched to Eli Lilly’s Mounjaro (tirzepatide). The findings could support Ozempic’s value proposition, although the analysis was observational rather than a head-to-head randomized trial. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Novo is expanding its obesity-drug pipeline. The company agreed to license global rights to Hengrui Pharma’s early-stage oral GLP-1/GIP drug HRS-1596 for up to $2.6 billion, including $300 million upfront and potential royalties. Novo also licensed Nanexa’s PharmaShell technology for possible monthly dosing programs, potentially improving convenience and extending its cardiometabolic pipeline. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: CagriSema delivered a favorable trial result. In the Phase 3 REIMAGINE 5 trial, a lower-dose combination of CagriSema produced 12.4% average weight loss after 60 weeks in adults with type 2 diabetes, giving Novo a result it can use to compete with Lilly’s tirzepatide-based medicines. Novo Nordisk Just Beat Lilly in a Trial
• Positive Sentiment: Share repurchases provide support. Novo continues its up-to-DKK 15 billion repurchase program, which may help earnings per share and signal management confidence.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.